Director at Perspective Therapeutics (CATX) awarded 50,000 stock options

Rhea-AI Filing Summary

Morich Frank reported acquisition or exercise transactions in this Form 4 filing.

Perspective Therapeutics, Inc. director Frank Morich received a grant of stock options covering 50,000 shares as his annual equity award for 2026. The Board of Directors approved the grant on January 26, 2026, with a grant date of March 2, 2026.

The option vests in full on March 2, 2027, provided Morich continues to serve through that date. Following this grant, he holds 50,000 stock options directly, reflecting a standard equity compensation award rather than an open-market share purchase or sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morich Frank

(Last) (First) (Middle)

C/O PERSPECTIVE THERAPEUTICS, INC.

2401 ELLIOTT AVENUE, SUITE 320

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Perspective Therapeutics, Inc. [ CATX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$5.35	03/02/2026(1)		A		50,000		(2)	03/02/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.

2. Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.

	/s/ Frank Morich by Chris Nenno, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CATX director Frank Morich report in this Form 4 filing?

Frank Morich reported receiving a grant of stock options for 50,000 shares as his 2026 annual equity award. The grant was approved by the board and is structured as a typical director compensation award, not an open-market stock purchase or sale.

How many Perspective Therapeutics (CATX) options were granted to Frank Morich?

Frank Morich was granted stock options covering 50,000 shares of Perspective Therapeutics common stock. These options represent his annual equity award for 2026 and are held directly, as disclosed in the Form 4 insider transaction details.

When was Frank Morich’s 50,000-share option grant at CATX approved and granted?

The option grant was approved by the Perspective Therapeutics Board of Directors on January 26, 2026, with an official grant date of March 2, 2026. This timing is specified in the filing’s footnotes describing the equity award.

What are the vesting terms of Frank Morich’s Perspective Therapeutics stock options?

The 50,000-share stock option granted to Frank Morich vests in full on March 2, 2027. Vesting is conditional on his continued service with Perspective Therapeutics through that vesting date, according to the disclosed footnote language.

Is Frank Morich’s Form 4 transaction a stock purchase or sale of CATX shares?

The Form 4 reports an acquisition of stock options via a grant, not a direct stock purchase or sale. The transaction is coded as an award of derivative securities, reflecting standard equity compensation for a board director.

How many Perspective Therapeutics options does Frank Morich own after this grant?

After the reported grant, Frank Morich directly holds 50,000 stock options in Perspective Therapeutics. The Form 4 indicates this total in the post-transaction holdings column, showing the impact of the new 2026 equity award grant.